Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells $239,287.36 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 3,104 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $77.09, for a total transaction of $239,287.36. Following the completion of the transaction, the chief financial officer directly owned 108,065 shares in the company, valued at $8,330,730.85. This trade represents a 2.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Revolution Medicines Trading Up 3.7%

RVMD opened at $78.78 on Friday. The firm has a 50 day simple moving average of $66.73 and a 200 day simple moving average of $49.27. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $81.49. The company has a market cap of $15.23 billion, a price-to-earnings ratio of -15.24 and a beta of 0.96. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.05 and a quick ratio of 8.05.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, November 5th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.39) by ($0.22). During the same period in the previous year, the business earned ($0.94) EPS. On average, sell-side analysts anticipate that Revolution Medicines, Inc. will post -3.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on RVMD. HC Wainwright increased their target price on Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. National Bankshares set a $80.00 price target on shares of Revolution Medicines in a research report on Friday, October 17th. The Goldman Sachs Group lifted their price objective on shares of Revolution Medicines from $65.00 to $73.00 and gave the stock a “buy” rating in a research note on Friday, September 12th. Needham & Company LLC upped their target price on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Buy” and a consensus price target of $78.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RVMD. FNY Investment Advisers LLC bought a new stake in shares of Revolution Medicines during the third quarter worth $110,000. Swiss Life Asset Management Ltd acquired a new position in Revolution Medicines in the 3rd quarter worth $293,000. Danske Bank A S bought a new position in Revolution Medicines during the 3rd quarter worth about $98,000. TCG Crossover Management LLC acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $20,383,000. Finally, Sender Co & Partners Inc. bought a new stake in shares of Revolution Medicines in the third quarter valued at about $403,000. Institutional investors own 94.34% of the company’s stock.

Trending Headlines about Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute‑304 (daraxonrasib) resectable pancreatic cancer trial — a near‑term clinical milestone that validates program progress and can support longer‑term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit‑taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.